| scholarly article | Q13442814 |
| P50 | author | Christoph Hiemke | Q88729617 |
| Marcella Rietschel | Q20742720 | ||
| P2093 | author name string | Matthias Müller | |
| Wolfgang Maier | |||
| Astrid Zobel | |||
| Aleksandra Dragicevic | |||
| Katja Grasmäder | |||
| Marie Luise Rao | |||
| Nikolaus Freymann | |||
| Petra Louise Verwohlt | |||
| P2860 | cites work | An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis | Q71365940 |
| Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography | Q72841994 | ||
| Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study | Q73108461 | ||
| Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world | Q73257076 | ||
| Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans | Q73710291 | ||
| Two-step cycle sequencing improves base ambiguities and signal dropouts in DNA sequencing reactions using energy-transfer-based fluorescent dye terminators | Q73982735 | ||
| A rating scale for depression | Q24564540 | ||
| Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine | Q28137902 | ||
| The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans | Q28254348 | ||
| Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele | Q28373588 | ||
| Pharmacokinetics of selective serotonin reuptake inhibitors | Q33837768 | ||
| Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. | Q33894411 | ||
| Pharmacogenetics and adverse drug reactions | Q34088287 | ||
| Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine | Q34093694 | ||
| CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages | Q34352560 | ||
| Pharmacokinetics of antidepressants: why and how they are relevant to treatment | Q40863434 | ||
| Antidepressants and drug-metabolizing enzymes--expert group report | Q41019100 | ||
| Pharmacogenetics of antidepressants: clinical aspects | Q41573014 | ||
| Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report | Q42289250 | ||
| Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients | Q43731923 | ||
| Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring | Q44530661 | ||
| Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. | Q50539540 | ||
| Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. | Q51000121 | ||
| Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. | Q52106400 | ||
| Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. | Q52980542 | ||
| Phenotyping of CYP2C19 with enantiospecific HPLCquantification of R- and S-mephenytoin and comparison with the intron4/exon5 G??? A-splice site mutation | Q53762253 | ||
| Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population | Q56832337 | ||
| Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology | Q57833810 | ||
| Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms | Q60678418 | ||
| The relationship between paroxetine and the sparteine oxidation polymorphism | Q60678422 | ||
| Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene | Q63241980 | ||
| Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography | Q67904800 | ||
| A simple method for DNA extraction from leukocytes for use in PCR | Q67979699 | ||
| Tricyclic antidepressants--blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry | Q69882600 | ||
| The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients | Q69903875 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 329-336 | |
| P577 | publication date | 2004-05-28 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting | |
| P478 | volume | 60 |
| Q90743053 | A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants |
| Q49627711 | Advancing psychiatric pharmacogenomics using drug development paradigms |
| Q37236791 | Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons |
| Q41892920 | CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression |
| Q46775272 | CYP2D6 genotype and phenotype determination in a Mexican Mestizo population |
| Q30939373 | Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population |
| Q35883249 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors |
| Q47161187 | Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children |
| Q37111336 | Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics |
| Q46907837 | Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms |
| Q46075268 | Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders |
| Q28553076 | Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data |
| Q40789842 | Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro |
| Q38379103 | Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy |
| Q35780023 | Exploring the role of drug-metabolising enzymes in antidepressant side effects |
| Q37898706 | Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism |
| Q46798692 | Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms |
| Q36536465 | Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants |
| Q37299922 | Investigation of CYP2D6 Gene Polymorphisms in Turkish Population |
| Q37334088 | Mechanisms of antidepressant resistance |
| Q40976937 | Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey |
| Q37343277 | No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications |
| Q38657429 | Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks |
| Q38731079 | Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways |
| Q38152886 | PharmGKB summary: venlafaxine pathway |
| Q35952367 | PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. |
| Q90575204 | Pharmacogenetics and Psychiatric Care: A Review and Commentary |
| Q39035865 | Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report |
| Q37989490 | Pharmacogenetics of antidepressant drugs: current clinical practice and future directions |
| Q34155796 | Pharmacogenetics of antidepressant response |
| Q37464458 | Pharmacogenetics of antidepressant response: an update |
| Q35026088 | Pharmacogenetics of antidepressants |
| Q38975693 | Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come? |
| Q92255814 | Pharmacogenomic Characterization in Bipolar Spectrum Disorders |
| Q36255125 | Pharmacogenomics in depression and antidepressants |
| Q37520997 | Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation |
| Q33326612 | Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample |
| Q43244977 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. |
| Q38885546 | Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders |
| Q37037058 | Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors |
| Q48249715 | Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors |
| Q36791600 | Risk and predictability of drug interactions in the elderly |
| Q36491587 | Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients |
| Q47894175 | Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? |
| Q47852468 | The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings |
| Q51846528 | The Promise and Reality of Pharmacogenetics in Psychiatry |
| Q26741187 | The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? |
| Q89959099 | The increasing challenge of the possible impact of ethnicity on psychopharmacology |
| Q35226451 | The promise and reality of pharmacogenetics in psychiatry |
| Q36582619 | Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance |
Search more.